[vc_row][vc_column][vc_column_text css_animation=”fadeInDown”]
Incyte Corporation (NASDAQ:INCY) Insider Sells $413,541.45 in Stock
[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column width=”1/2″][vc_column_text css_animation=”fadeInLeft”]Incyte Corporation (NASDAQ:INCY) insider David W. Gryska sold 3,915 shares of the stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $105.63, for a total transaction of $413,541.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of Incyte Corporation (NASDAQ INCY) traded down $6.52 during mid-day trading on Monday, reaching $98.95. The company had a trading volume of 2,526,476 shares, compared to its average volume of 1,934,999. Incyte Corporation has a 52-week low of $98.49 and a 52-week high of $153.15. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.82 and a quick ratio of 4.81.
Incyte Corporation (NASDAQ:INCY) last issued its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.06 by $0.11. The firm had revenue of $381.50 million during the quarter, compared to analysts’ expectations of $360.34 million. Incyte Corporation had a negative return on equity of 12.91% and a negative net margin of 10.90%. Incyte Corporation’s quarterly revenue was up 41.6% compared to the same quarter last year. During the same period last year, the business earned $0.19 earnings per share. sell-side analysts predict that Incyte Corporation will post -1.33 earnings per share for the current fiscal year.[/vc_column_text][/vc_column][vc_column width=”1/2″][vc_raw_html]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[/vc_raw_html][vc_raw_html]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[/vc_raw_html][/vc_column][/vc_row][vc_row][vc_column][vc_column_text css_animation=”fadeIn”]A number of analysts have recently issued reports on INCY shares. J P Morgan Chase & Co reissued a “buy” rating and issued a $149.00 price target on shares of Incyte Corporation in a research report on Thursday, August 31st. Argus reissued a “buy” rating and issued a $150.00 price target on shares of Incyte Corporation in a research report on Wednesday, September 13th. Jefferies Group LLC reissued a “buy” rating and issued a $148.00 price target on shares of Incyte Corporation in a research report on Thursday, July 27th. Goldman Sachs Group, Inc. (The) started coverage on shares of Incyte Corporation in a research report on Friday, October 6th. They issued a “buy” rating and a $160.00 price target for the company. Finally, BidaskClub downgraded Incyte Corporation from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Seven research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $144.98.
A number of hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in Incyte Corporation by 11.1% in the second quarter. Vanguard Group Inc. now owns 17,125,542 shares of the biopharmaceutical company’s stock worth $2,156,276,000 after purchasing an additional 1,709,685 shares during the period. Capital International Investors lifted its position in Incyte Corporation by 1.4% in the third quarter. Capital International Investors now owns 6,494,566 shares of the biopharmaceutical company’s stock worth $758,176,000 after purchasing an additional 87,369 shares during the period. BB Biotech AG lifted its position in Incyte Corporation by 0.7% in the second quarter. BB Biotech AG now owns 3,514,822 shares of the biopharmaceutical company’s stock worth $442,551,000 after purchasing an additional 25,000 shares during the period. Matrix Capital Management Company LP lifted its position in Incyte Corporation by 28.3% in the second quarter. Matrix Capital Management Company LP now owns 1,796,716 shares of the biopharmaceutical company’s stock worth $226,225,000 after purchasing an additional 396,716 shares during the period. Finally, UBS Asset Management Americas Inc. lifted its position in Incyte Corporation by 10.7% in the second quarter. UBS Asset Management Americas Inc. now owns 1,636,035 shares of the biopharmaceutical company’s stock worth $205,993,000 after purchasing an additional 158,574 shares during the period. 89.60% of the stock is owned by hedge funds and other institutional investors.
Incyte Corporation Company Profile
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).[/vc_column_text][vc_raw_html]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[/vc_raw_html][/vc_column][/vc_row]